Sequence information
Variant position: 482 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 494 The length of the canonical sequence.
Location on the sequence:
QPLPHCSVILKMQPFQVRLQ
P RGMGAHSPGQNQ
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human QPLPHCSVILKMQPFQVRLQP RGMGAHSPGQNQ---
Mouse QPQPYAGINLPIPPFQVRLQP RNLAPQDQGERP
Rat QPLPYTGINLLIPPFQVRLQP RNLAPQDQGQKS
Pig QPHPHSGINLKVQPFQVRLQP RGGRGEGPGPR-
Bovine QPDPYCGVNLKVQPFQVRLQP RGVEA-GAWESA
Cat RPRSHCGINLTMQPFQVRLQP RGAVAPGPSQHQ
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 494
Steroid 21-hydroxylase
Beta strand
478 – 482
Literature citations
Functional analysis of two recurrent amino acid substitutions in the CYP21 gene from Italian patients with congenital adrenal hyperplasia.
Barbaro M.; Lajic S.; Baldazzi L.; Balsamo A.; Pirazzoli P.; Cicognani A.; Wedell A.; Cacciari E.;
J. Clin. Endocrinol. Metab. 89:2402-2407(2004)
Cited for: VARIANTS AH3 THR-15; LEU-30; LEU-281 AND SER-482; CHARACTERIZATION OF VARIANTS AH3 THR-15 AND SER-482;
Functional and structural consequences of nine CYP21A2 mutations ranging from very mild to severe effects.
de Paula Michelatto D.; Karlsson L.; Lusa A.L.; Silva C.D.; Oestberg L.J.; Persson B.; Guerra-Junior G.; de Lemos-Marini S.H.; Barbaro M.; de Mello M.P.; Lajic S.;
Int. J. Endocrinol. 2016:4209670-4209670(2016)
Cited for: VARIANTS AH3 MET-12; PHE-113; 389-GLN--ALA-391 DEL AND PRO-450; VARIANTS CYS-16; GLY-202; LEU-267 AND MET-450; CHARACTERIZATION OF VARIANTS AH3 MET-12; PHE-113; 389-GLN--ALA-391 DEL; PRO-450 AND SER-482; CHARACTERIZATION OF VARIANTS CYS-16; GLY-202; LEU-267 AND MET-450; FUNCTION; CATALYTIC ACTIVITY; BIOPHYSICOCHEMICAL PROPERTIES;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.